BioMarin drops lower dose of its hemophilia gene therapy as it eyes submissions by year-end

In its race to be the first to submit a gene therapy for review in hemophilia, BioMarin Pharmaceutical is dropping development of a lower dose of its valrox treatment amid plans to get its applications into the hands of regulators before the end of the year.